金龙固本合剂治疗支气管哮喘缓解期的(宿痰伏肺证)随机对照试验研究  

Randomized Controlled Trials on Asthma in Remission(Latent Phlegm in Lung Syndrome) by Jinlong Guben Heji(金龙固本合剂)

作　　者：石绍顺[1] 于雪峰[1] 李国信[1] 李中宇[1] 乔世举[1] 

机构地区：[1]辽宁中医药大学附属第二医院,辽宁沈阳110034

出　　处：《中医药导报》2016年第5期78-80,共3页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家中医肺病临床重点专科;重点学科建设项目

摘　　要：目的:评价金龙固本合剂治疗支气管哮喘缓解期(宿痰伏肺证)的临床疗效与安全性。方法:将241例支气管哮喘缓解期(宿痰伏肺证)患者随机分为治疗组与对照组,治疗组给予金龙固本合剂连续口服4个月,对照组不予干预,观察治疗后及随访1年疾病的复发率、国际哮喘控制测试表(asthma control test,ACT)、外周血嗜酸性粒细胞(eosinophil,EOS)计数等指标。结果:治疗组总有效率为96.5%,对照组总有效率为62.7%,两组比较,差异有统计学意义(P<0.01);两组国际哮喘控制测试表(ACT)结果比较,差异有统计学意义(P<0.01);两组外周血嗜酸性粒细胞(EOS)计数比较,差异有统计学意义(P<0.01)。结论:金龙固本合剂能降低哮喘患者外周血嗜酸性粒细胞水平,明显减少支气管哮喘发作次数,预防支气管哮喘急性发作,并且未发现明显不良反应。Objective： To obsreve the effects and security of Jinlong Guben Heji on asthma in remission. Methods： The 241 cases of patients with asthma in remission （Latent Phlegm in Lung Syndrome） patients were randomized to the treatment and control groups. Patients were treated with Jinlong Guben Heji in the treatment group, for 4 months; Patients got no intervention in control group. The recurrence rate, Asthma Control Test （ACT） and Eosinophil count etc were observed lyear after treatment. Results： The total effective rate was 96,5% in treatment group and 62.7% in the control group, and the difference was significant （P〈0.01）; There was significant difference on Asthma Control Test （ACT） （P〈0.01）, and Eosinophil count （P〈0.01）, between the two groups. Conclusion： Jinlong Guben Heji can reduce the Eosinophil count and the frequency of bronchial asthma and prevent acute attack of bronchial asthma in patients with asthma; Jinlong Guben Heji treating asthma in remission is sate and effective.

关 键 词：支气管哮喘 缓解期 宿痰伏肺证 金龙固本合剂 

分 类 号：R256.1[医药卫生—中医内科学]